Asia Fresh News

CardioComm Solutions technology recognized as an enabler for quality remote access diagnostic interactions between consumers, patients, and physicians.

MOUNTAIN VIEW, Calif., Sept. 25, 2012 /PRNewswire/ — Based on completion of their analysis of the cardiac rhythm monitoring technology industry, Frost & Sullivan recognizes CardioComm Solutions, Inc. (“CardioComm Solutions”) with the 2012 North American Frost & Sullivan Award for Enabling Technology. CardioComm Solutions is especially recognized for leveraging its SMART Monitoring technology to launch a fully scalable and cost-effective electrocardiograph (ECG) and arrhythmia monitoring solution.

CardioComm Solutions has demonstrated industry leadership by introducing their ECG management and monitoring solutions, well-known in the medical establishment space, into the consumer market well ahead of its time. CardioComm Solutions is also the first company to offer over-the-counter (OTC) cardiac rhythm monitoring devices with the option of physician driven ECG interpretive services.

CardioComm Solutions focused on what it knew best, ECGs, and came up with the HeartCheck™ ECG Handheld Monitor, HeartCheck™ PEN, and SMART Monitoring service as an extension of their proprietary medical monitoring technologies. SMART Monitoring powers the HeartCheck™ devices using the company’s proprietary GEMS™ and GlobalCardio™ software. The resulting cardiac monitoring solution is a globally expandable ECG and arrhythmia monitoring solution.

The prescriptive HeartCheck™ devices are portable, handheld, user-friendly devices which can take accurate readings anytime in just 30 seconds. The HeartCheck™ ECG monitor can store up to 200 ECG recordings. The OTC-cleared HeartCheck™ PEN can hold up to 20 heart rhythm recordings. Recorded data is rapidly transferred through the SMART Monitoring solution to a physician or medical call center through CardioComm Solutions’ own GlobalCardio™ software. The HeartCheck™ PEN SMART Monitoring solution incorporates the company’s consumer version of its proprietary GEMS™ software known as GEMS™ Home.

As further proof of its foresight, CardioComm Solutions is completing the rewriting of both its ECG management source code as well as ECG viewer programs to ensure compatibility with any new operating system (OS) that might come up in the next eight to ten years.

“CardioComm Solutions believes in a one-to-many, software-to-device relationship that allows its clients, whether they are hospitals, medical centers, or physicians’ offices, the flexibility to buy the ECG monitoring hardware solution of their choice based on brand loyalty, cost, or workflow preferences,” said Frost & Sullivan Research Analyst Darshana De.

The company is also focusing on developing product solutions for other biometric monitoring devices that can be used as OTC or prescriptive devices to measure basic and advanced biometric parameters, such as body weight, blood pressure, temperature, pulse oxymetry, and glucose.

CardioComm Solutions intends to persist with its device-agnostic approach to introduce software products solutions to the consumer market using its prudential prescription-based medical software. The company also plans to penetrate the sports and hard-labor market and provide effective monitoring for people who are active at the time of monitoring, such as during sports training.

Acknowledging patients’ proactive knowledge garnering about a new device and the role played by governments and medical reimbursement groups in stoking technology acceptance, CardioComm Solutions is holding discussions with government and community medical authorities on enabling remote and mobile monitoring technology. It also provides physicians with direct exposure to its ECG technology offerings to improve awareness and adoption.

“CardioComm Solutions’ strategy is to collaborate with companies, rather than compete with them, to build superior products and solutions,” noted Darshana. “It is in discussion with several foreign companies that have affordable hardware technologies but lack the expertise to activate these technologies with the appropriate software solutions.”

CardioComm Solutions is looking to sign more collaborative deals involving the expansion of GEMS™ and GlobalCardio™ licensing, greater use and sale of HeartCheck™ devices as point-of-care ECG monitors, and, finally, commercialization of its community and at-risk population arrhythmia screen tools.

These strategies have paid off for CardioComm Solutions, with end users from South America, Europe, Middle East, and Asia evincing interest in its solutions. Further, representatives from more than 50 countries have inquired about distribution rights for their products, indicating excellent prospects for market expansion.

“We were pleased to have been selected as a potential candidate for this award. Winning the 2012 award clearly speaks to our commitment of bringing disruptive technologies forward that will enable government sectors, consumers, patients and their doctors to close the gap between timely diagnosis and timely treatment of common and potentially life alerting cardiac disorders. Our company was recognized by both collaborators and competitors in Frost and Sullivan’s review of the North American markets, highlighting that our progressive sales, marketing and R&D efforts are being taken not of ,” said Etienne Grima, CEO of CardioComm Solutions. “We are appreciative and respectful of the work completed by Frost and Sullivan and will endeavor to show they were right in selecting our company”.

Each year Frost & Sullivan presents this award to the company that has developed a technology that can benefit or revolutionize the industry. The award recipient has developed a system or enabling component of a system that removes a significant obstacle in the development of technology. The technology developed enables the creation of new products or modification of existing products to target new applications.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About CardioComm Solutions, Inc.

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, British Columbia, Canada.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact:

Mireya Espinoza
P: +1-210-247-3870
F: +1-210-348-1003
E: mireya.espinoza@frost.com

Written by asiafreshnews

September 26, 2012 at 3:00 pm

Posted in Uncategorized

Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management, Finds Frost & Sullivan

Health plans require clear evidence of the clinical utility of biomarker tests

MOUNTAIN VIEW, Calif., Sept. 25, 2012 /PRNewswire/ — With technological advances in diagnostics, physicians may shortly have real-time information about the tumor at various stages of patient management. Future cancer biomarker tests will also be multiplexed and comprise multiple biomarker types. As personalized medicine involves matching effective treatments to individuals based on their genetic disposition and other reliable factors, highly specific biomarkers are critical for identifying likely responders from non-responders.

New analysis from Frost & Sullivan’s (http://www.healthcare.frost.com/) Analysis of the U.S. Cancer Biomarker Testing Market research finds that the health plan reimbursement market earned revenues of US$7.86 billion in 2011 and estimates this to reach US$11.46 billion in 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

“Effective cancer patient management relies on specific and useful biomarkers that enable oncologists to diagnose, determine suitable therapies, continuously monitor response to therapy, or monitor tumor progression,” said Frost & Sullivan Industry Analyst Winny Tan, Ph.D. “Consequently, personalized medicine is becoming a mainstream concept and the approaches to personalized medicine are increasingly understood by physicians and patients.”

Market participants are gearing up for exciting times in the market, as generation sequencing becomes more affordable and cost competitive with the prices of current tests that look at a single-mutation. Additionally, the accelerated trend of out-licensing and therapy-companion diagnostic co-development across the industry is likely to raise the number of new cancer biomarker tests entering the market.

These new tests will be highly complex to perform and interpret. Following this, cancer testing will become centralized and more cancer biomarker tests are likely to be commercialized from multi-center research consortiums.

Furthermore, the large number and variety of industry partnerships suggest that collaboration is vital to compete in the market. Companies could partner with each other for companion diagnostic development, licensing agreements, clinical trial collaboration, R&D collaborations, distribution agreements, and other commercialization interests.

While technology is advancing cancer patient management, it is also escalating the costs of cancer biomarker testing. Currently, new detection platforms such as next-generation sequencing are still more expensive than traditional slide-based cancer testing, and this deters several potential buyer groups.

The commercial success of any diagnostic test depends on the clear evidence of its clinical utility; however, few biomarker discovery programs participate in the clinical validation of new biomarkers. The high costs of clinical validation and limited ROI are some of the reasons that few biomarkers have translated to diagnostic tests.

The market will also be affected by changes in the regulatory sphere. The increasing frequency of warning letters issued to clinical laboratories offering laboratory developed tests (LDTs) precedes the fact that the Food and Drug Administration (FDA) will exercise greater oversight over LDTs in the future. The final guidance on this issue will be announced by the FDA next year.

“Test developers should anticipate greater demands for proof for both assay performance and clinical utility,” noted Tan. “Private and government health plans will require clear evidence of the clinical utility and the impact of the test on patient health to compare it with the best alternative.”

Once participants demonstrate the value of new biomarker types, their pipeline will expand and subsequently, the market will grow at a faster rate.

Analysis of the U.S. Cancer Biomarker Testing Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: Analysis of the U.S. Clinical Laboratory Market, Diagnostics Testing and Technologies for Solid Tumor (FFPE) Specimens End-user Analysis, and Demand Analysis of U.S. Cancer Sample Prep Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

Analysis of the U.S. Cancer Biomarker Testing Market

NB1D-52

Contact:
Britni Myers
Corporate Communications – North America
P: +1-210-477-8481
F: +1-210-348-1003
E: britni.myers@frost.com

http://www.frost.com

Written by asiafreshnews

September 26, 2012 at 2:50 pm

Posted in Uncategorized

Frost & Sullivan: Setting the Stage for What’s Next in Medical Devices

Companies attempt to adapt to the new reality of the evolving healthcare landscape

MOUNTAIN VIEW, Calif., Sept. 25, 2012 /PRNewswire/ — The medical device industry continues to be one of the most vital and dynamic sectors of the U.S. economy and a leading force in the revolution that is transforming the U.S. healthcare system. However, the industry is undergoing a transition to adapt to new business models that are changing the way care is delivered and paid for in the United States.

New analysis from Frost & Sullivan’s (http://www.medicaldevices.frost.com) 2012 United States Medical Devices Outlook finds total market revenues in 2011 were $102.1 billion, with a forecast of $156.8 billion projected in 2018. The overall compound annual growth rate (CAGR) for the forecast period is a modest 6.3 percent. While top-line growth is a virtual certainty, cost-containment initiatives in the healthcare industry are forcing pricing pressure with a medical device excise tax to go into effect in 2013 that could strain margins for most companies.

For the full multimedia experience of this release, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

“In retrospect, the medical device market witnessed unprecedented growth between 1995 and 2005. New technologies helped spur a revolution with minimally invasive tools and implants that improved function and safety,” said Frost & Sullivan Advanced Medical Technologies Industry Manager Venkat Rajan. “These novel developments allowed for new treatments and an expansion of addressable conditions.”

That growth, coupled with the potential impact of the baby boomer population, led many in the industry to assume that the marketplace was recession-resilient, if not recession-proof. However, the impact of the global economic crisis in 2008 combined with healthcare reform measures aimed at cost containment have significantly altered those expectations. In order to better align with the realities of the current market, a number of companies have undergone significant restructuring, such as major divestitures, staff cuts, and turnover in senior management.

“In spite of the challenges, that is not to say that there are not significant opportunities in the market that can be taken advantage of,” said Rajan. “A historic surge in demand resulting from an aging population with escalating incidence rates for chronic disease is creating new needs and customer requirements. Furthermore, significant research breakthroughs and leaps in technology are drastically advancing the state of modern medicine.”

Cutting edge companies are targeting products that fit in the vision of where healthcare is heading, as opposed to where it is now. They have realized it is not just about innovations to their products, but the business model as well. Decisions are not made purely on clinical efficacy, but must also take into account factors like ease of use, reimbursement, long term cost of care, wellness, prevention and other advanced healthcare outcome measures.

The 2012 United States Medical Devices Outlook is part of the Advanced Medical Technologies Growth Partnership Services program, which also includes research in the following markets:

Surgical Tools and Medical Implants
Medical Imaging Systems
Patient Monitoring and Diagnostic Tools
Chronic and Acute Disease Management Treatment Products

All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

2012 United States Medical Devices Outlook
NB3E-54

Contact:
Britni Myers
Corporate Communications – North America
P: +1-210-477-8481
F: +1-210-348-1003
E: britni.myers@frost.com
http://www.frost.com

Written by asiafreshnews

September 26, 2012 at 2:42 pm

Posted in Uncategorized

Mexico Tourism Board and the Embassy of Mexico Host Flight of the Butterflies in 3D World Premiere

WASHINGTON /PRNewswire/ — TheGovernment of Mexico, through the Mexico Tourism Board and the Embassy of Mexico hosted the world premiere of “Flight of the Butterflies” yesterday evening at Smithsonian’s National Museum of Natural History in Washington, D.C. More than 400 guests, in the presence of Mexican President Felipe Calderon, gathered for the IMAX® 3D screening which tells the story of the Monarch Butterfly – one of the great natural mysteries of the world.
Produced by SK Films, a Canadian production company, and supported by the National Science Foundation, “Flight of the Butterflies” chronicles the true story of an intrepid scientist’s 40-year search to find Monarch butterflies’ secret hideaway while overwintering in Mexico.
The award-winning production team, including executive producer Jonathan Barker and Oscar® winner Peter Parks, captures the year-long migration cycle of hundreds of millions of Monarch butterflies, from Canada, through the United States to remote 10,000-foot-high peaks in the Sierra Madre Mountains of Mexico – and back – through generations.
The film also represents a strong partnership amongst the U.S., Canada and Mexico to tell the untold story of Dr. and Mrs. Fred Urquhart and share the natural phenomenon of a tiny creature’s epic migration with viewers across the world.
Since 2006 President Felipe Calderon has distinguished himself as a world leader in sustainability, living out his personal mandate to preserve the natural wonders of Mexico. A native of Morelia, Michoacan who grew up near the butterfly sanctuaries, President Calderon’s says, “We must remain committed to the conversation of these fragile creatures and their threatened habitats.”
In 2008 UNESCO declared the Monarch butterfly reserve in Mexico a World Heritage Site. While the WWF classified the Monarch as a “near threatened” species, the Mexican government and leading conservations organizations such as FMCN (Fondo Mexicano para la Conservacion de la Naturalez, A.C.) will continue to enforce measures to preserve the butterflies and their sanctuaries.
SECTUR, Mexico’s federal Ministry of Tourism, Mexico Tourism Board, the state of Michoacan and the state of the Mexico, as well as governmental and international environmental institutions sponsored the film.
For more information or to arrange an interview, please contact:
Jennifer Risi
Ogilvy Public Relations Worldwide
+1-646-240-6297
Source: Mexico Tourism Board

Written by asiafreshnews

September 26, 2012 at 2:35 pm

Posted in Uncategorized

Tagged with Travel

SHL Wins Award for Excellent HR Service

Hong Kong Institute of Human Resources Management presents SHL with an Excellent HR Service Provider Award for Education & Training
HONG KONG /PRNewswire/ — SHL, global leader in talent measurement, today announced it has won the ‘Excellent HR Service Provider Award for Education & Training’ by the Hong Kong Institute of Human Resources Management (HKIHRM), the professional body that aims to develop and enhance professional standards in HR management in Hong Kong SAR.
In its 35th year of celebrating excellence and innovation in the HR sector, the Annual Human Resources Awards are highly regarded throughout the industry for acknowledging organizations’ outstanding contribution and best practice. The judging panel comprised of representatives from HKIHRM, and professionals from public and private sectors.
Up against strong competition, SHL was delighted to secure this title. Stuart Hedley, Managing Director, SHL Hong Kong comments on the win: “We’re both thankful to the HKIHRM for this award and very pleased that through the award, HKIHRM recognise and acknowledge SHL in providing true innovation and robust practice that increases objectivity and effectiveness of talent selection and streamlines recruitment processes for our clients across Asia.”
SHL’s capabilities are built on over 30 years of experience and innovation in the delivery of talent assessment solutions. Over the last few years, SHL has made significant investment in its training programmes, Chief Customer Officer, Robert Morgan said: “As the global leader in talent measurement, SHL is dedicated to equipping organisations with people insight that helps them identify and develop the right talent to transform business performance.” Morgan continues: “Our training courses and e-learning programs are completed by thousands of HR practitioners a year, across more than 50 countries. Winning this award is a great accomplishment.”
The President of Asia, Africa and Middle East, Mike Tims, said: “This accolade reinforces our commitment to international expansion. The company opened its first office in Hong Kong 29 years ago and has since expanded its footprint in China by establishing a wholly owned business unit in 2011. With a network of offices in India, an office in Singapore and partners across the whole of South East Asia, SHL increasingly derives its growth from Asia.”
“On behalf of Hong Kong Institute of HKIHRM, I congratulate SHL Hong Kong Limited in winning the Award. SHL’s initiative has received unanimous recognitions from the panel of judges in terms of its clearly-defined objective and flawless execution, which is an excellent example of outstanding HR best practices contributing to business success,” said Mr. Francis Mok, President, HKIHRM.
Winners of the HR Excellence Awards were announced at the ceremony held on 21 September 2012 at Conrad Hong Kong. To find out more about HKIHRM HR Excellence Awards visit: http://www.hkihrm.org/award
Notes to Editors:
About SHL Training
SHL Training gives clients the skills to deliver real business benefits through assessment and prove the value to their business. We help clients to leverage the power of SHL People Intelligence by teaching them how to successfully apply the world’s best personality and ability assessments. They can also learn HR skills they need to implement best-practice talent management within their organisation and ensure quantifiable business results.
SHL courses are attended by over 3,000 delegates a year across more than 50 countries, delivered by experienced HR practitioners and are based on internationally recognised standards.
Many of SHL programmes make extensive use of e-learning as well as classroom settings, and can be delivered in-house to help tailor the training more closely to client’s needs. Upon completing a course, delegates are provided access to our Training Academy portal for resources and best-practice guidelines. SHL course offerings include: Ability and Personality Assessment course, HR Skills course and Expert Master Classes and workshops.
For more information, visit http://www.shl.com/uk/expertise/training-services.
About SHL
SHL is the leader in talent measurement solutions, driving better business results for clients through superior people intelligence and decisions – from hiring and recruiting, to employee development and succession planning. With a presence in over 50 countries, SHL delivers more than 25 million assessments annually in over 30 languages – allowing over 10,000 business customers to benefit from both global expertise and local insight. Along with its world-class consulting practices and 24-hour support center, SHL clients can access over 1,000 assessments through an easy-to-use technology platform. SHL was acquired in 2012 by CEB, the leading member-based advisory company. By combining the best practices of thousands of member companies with advanced research methodologies and human capital analytics, CEB equips senior leaders and their teams with insight and actionable solutions to transform operations. Headquartered in London, UK, SHL has offices in North and South America, Europe, the Middle East, Africa, Asia and Australia/New Zealand. For more information, visit http://www.shl.com.
For media enquiries, please contact:
Karen Wong
karen.wong@shl.com
+852 2837 3907
Source: SHL

Written by asiafreshnews

September 26, 2012 at 1:04 pm

Posted in Uncategorized

Tagged with Business, Finance

Octoshape and NetRange Forge Alliance Powering OTT IPTV Enabled Smart TVs

ATLANTA and HAMBURG, Germany/PRNewswire/ —
Partnership Brings Infinite HD-M to NetRange Powered Smart TVs Enabling the Transition From Broadcast TV to Broadband TV
NetRange, a global provider of Smart TV solutions, and Octoshape, an industry leader in cloud-based streaming technology, have partnered to facilitate the next generation in broadband television – transitioning from “Broadcast TV” to “Broadband TV”. The Octoshape Infinite HD-M multicast technology will be integrated into NetRange Smart TV portals and will enable TV quality, TV scale and TV economics over unmanaged IP networks.
The concept, also called “Triple OTT”, will allow consumers to watch linear TV via the DVB-Platform as they do today, but also add the ability to view unlimited amount of linear channels in broadcast quality via the public Internet, including access to Smart TV applications and services. Broadcasters and media companies will benefit from a range of new business models and gain unlimited, global reach for HD quality video delivery on Smart TVs. Network operators and ISPs will benefit as the life cycle of already existing broadband infrastructure such as ADSL2+ will be extended since the technology makes existing networks much more efficient to deliver large volumes of content.
“With Triple OTT, we deliver exactly what the consumer wants. Besides linear TV based on DVB and our portfolio of Smart TV applications, Octoshape will enable our devices and our content partners to make more content available at the highest quality with flat fee per channel pricing,” said Jan Wendt, Founder and CEO of NetRange. “Octoshape’s Infinite HD-M technology will become a major component in our OTT strategy. Their focus and reputation for providing for large scale broadband TV audiences coupled with its unique technology enabling global video quality will provide a new platform for content owners and device manufacturers with unparalleled consumer video experiences.”
The partnership integrates Octoshape’s Infinite HD-M Federated Multicast platform into NetRange-powered Smart TV portals. Infinite HD-M enables large volumes of broadband TV consumption to be delivered efficiently over last mile networks without requiring the vast infrastructure upgrades necessary with traditional video delivery platforms.
With more than 400 customers, NetRange is one of the world’s largest service providers for Smart TV solutions and is also one of the world’s most successful service providers for the development of Smart TV applications and services. Working for clients like ITN news, maxdome, Mercedes-Benz, Brainpool, Tagesschau and the Bauer Media Group, NetRange has developed applications and services not only for its own portal, but also for other current leading Smart TV portals, such as Samsung, LG and Philips.
“The partnership with NetRange is an explosive catalyst in the ecosystem,” said Michael Koehn Milland, CEO of Octoshape. “The combination of the consumer friendly NetRange Smart TV portal with the quality, scale, and economic aspects of the Infinite HD-M platform will create an unbeatable consumer video experience on the broadband connected television.”
Telco and cable operators that are part of the Infinite HD-M Federated network receive the signals via native IP Multicast in a way that allows them to easily manage large volumes of traffic without upgrading their Internet capacity. Octoshape’s federated linear broadband TV ecosystem will continue to expand globally throughout 2012 in carefully planned phases adding content contribution partners, Tier 1 broadband providers, connected television manufacturers and conditional access providers.
About Octoshape
Streaming media innovator Octoshape provides the enabling technology required to bring TV Quality, TV Scale and TV Economics to the public Internet. The company is writing the next chapter of content delivery for broadband IPTV services. The Octoshape approach is more scalable, flexible and affordable than traditional content delivery (CDN) schemes, while providing feature-rich, high-quality viewing to the largest of audiences. For more information visit http://www.octoshape.com.
About NetRange
NetRange is a global provider of white label, brand independent Smart TV portal solutions. NetRange is operating integrated worldwide full-service Smart TV portals for major clients such as Sharp, Loewe, Vestel and HD+ (a subsidiary of SES Platform Services).
For more information please contact:
For Octoshape
Jessica Slezak
Phone: +1-801-305-1447

For NetRange
Margit Lehmann
Phone: +49-40-280-953-0
Fax: +49-40-280-953-11
Email: margit.lehmann@netrange.com
Web: http://www.netrange.com
Source: NetRange MMH GmbH

Written by asiafreshnews

September 26, 2012 at 12:46 pm

Posted in Uncategorized

Tagged with General News

Frost & Sullivan: Advanced Performance Characteristics of Polymers Expands Market for Plastics in Medical Devices

Despite environmental concerns, plastics become dominant materials used in medical devices

MOUNTAIN VIEW, Calif., Sept. 25, 2012 /PRNewswire/ — The increasing average age of the U.S. population is creating a vast market for medical treatment, especially minimally invasive procedures. In a fragile economy, patients prefer minimally invasive methods, boosting the consumption of plastic polymers, which are ideal for use in catheters and medical tubing.

A new comprehensive Frost & Sullivan (http://www.chemicals.frost.com) study Analysis of the Plastic Polymers in Medical Devices Market, finds that the total North American market volume of plastics in medical devices totalled 1,370.0 million pounds, corresponding to revenues in excess of US$1 billion. By 2018, revenues are expected to equal US$1.45 billion, fuelled by a compound annual growth rate of 5.2 percent. Commodity plastics such as polyvinyl chloride (PVC), polyethylene (PE) and polypropylene (PP) accounted for most of the total volume.

If you are interested in more information on this research, please send an email to Jeannette Garcia, Corporate Communications, at jeannette.garcia@frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state, and country.

“While the baby boomer population has surpassed 76 million, the number of young people requiring medical care is also on the rise,” said Shomik Majumdar, Vice President, Chemicals and Materials. “The higher incidence of lifestyle diseases, along with governments’ keener focus on improving healthcare, drives the demand for medical devices and consequently, plastic polymers.”

Reduced hospital stay to lower healthcare costs will increase the focus on homecare medical devices and enhance the demand for dialysis kits and diabetes control devices. This will therefore augment the need for medical plastics. Plastics are preferred in homecare devices due to their flexibility, durability and light weight.

On the flip side, there are some concerns about the use of polymers in medical devices, especially in terms of degradability and recyclability. Nevertheless, this environmental issue has not reached a critical state. The low price of commodity resins like PE, PP, PVC and their high performance characteristics makes them irreplaceable in the near future.

“There has also been heightened focus on engineered polymers such as co-polyether-ester elastomers (COPE), polyether block amides (PEBA), and acetal chemistries that have more advanced performance properties for niche, technologically advanced healthcare applications, such tissue engineering and implants,” said Research Analyst Tridisha Goswami. “These new materials will expand the scope of plastic polymers’ application and propel the market.”

Analysis of the Plastic Polymers in Medical Devices Market is part of the Chemicals & Materials Growth Partnership Services program that also includes research in construction & utility, food and animal nutrition, packaging, pharmaceuticals, cosmetics, transportation, and personal protection. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated extensive primary research across the industry value chain.

About Frost & Sullivan

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

Analysis of the Plastic Polymers in Medical Devices Market
NA67-39

Contact:
Jeannette Garcia
Corporate Communications – North America
P: +1-210-477-8427
E: jeannette.garcia@frost.com

http://www.frost.com

Written by asiafreshnews

September 26, 2012 at 12:37 pm

Posted in Uncategorized

Sands Cotai Central Phase Two Opening Sets Highest Weekend Visitation for All Sands China Properties in 2012

Diverse offerings a key driver of Macao tourism
MACAO /PRNewswire/ — The second phase opening of the Sands® Cotai Central integrated resort on September 20 has marked its first achievement in just three days, as Sands China Ltd.’s overall visitation numbers for last weekend (September 21 to 23) reached an all-time record for 2012 at approximately 500,000, greater than the previous record from the Chinese New Year weekend. The newest offering at Sands Cotai Central’s second phase, which features the world’s largest Sheraton Hotel, is a strong testament to Sands China’s continuous effort to elevate Macao’s status as one of Asia’s leading destinations for business and leisure travelers.

Eager crowds rush to be among the first to experience the latest facilities at Sands Cotai Central on Thursday, September 20, as the integrated resort unveiled the second phase of its development, featuring the opening of the world’s largest Sheraton hotel. The weekend’s property visitation numbers set a new record for Sands China Ltd., with close to 500,000 people visiting the company’s integrated resorts in Macao.
“We are very pleased with the customer response to our new facilities at Sands Cotai Central and it bodes well for the long term growth of Cotai,” said Edward Tracy, President and Chief Executive Officer of Sands China Ltd. “Sands China Ltd. strives to diversify Macao tourism industry through bringing in the absolute best in hotels, restaurants, shops and entertainment events. The addition of Sheraton Macao to Sands Cotai Central means Sands China’s integrated resorts on the Cotai Strip will soon have a combined 9,000 rooms on offer — a significant step towards developing Macao into a world centre of business, tourism and leisure.”
About Sands China Ltd.
Sands China Ltd. (HKEx: 1928, Sands China or the Company) is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE:LVS), and is listed on the Stock Exchange of Hong Kong Limited. Sands China is the largest operator of integrated resorts in Macao. The Company’s Cotai Strip® developments include The Venetian® Macao-Resort-Hotel, The Plaza™ Macao and Sands® Cotai Central. The Company also owns and operates the Sands® Macao on the Macao peninsula. The Company’s integrated resorts contain a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities, a wide range of restaurants, shopping malls, world-class entertainment at the CotaiArena™ and the Venetian Theatre, and a high-speed CotaiJet™ ferry service between Hong Kong and Macao. The Company’s property development projects on Cotai have the goal of transforming Cotai into Asia’s premier entertainment and business destination.
For more information, please visit http://www.sandschinaltd.com.
Media contact:
Public Relations, Venetian Macau Limited
Mabel Wu
Venetian Macau Limited
Tel: +853 8118 2268
Email: mabel.wu@venetian.com.mo
Source: Sands China Ltd.

Written by asiafreshnews

September 26, 2012 at 10:47 am

Posted in Uncategorized

Tagged with Travel

UBM Asia, the World’s Leading Organiser of B2B Jewellery and Gem Fairs, Expands its Global Jewellery Portfolio to Singapore and Europe